JPMORGAN CHASE & CO - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,465,097
-25.7%
167,964
+6.3%
0.00%
-100.0%
Q2 2023$4,662,344
+38.6%
157,992
+8.2%
0.00%
Q1 2023$3,364,000
+65654.5%
145,987
-20.6%
0.00%
-100.0%
Q4 2022$5,116
-99.8%
183,976
+69.8%
0.00%
Q3 2022$3,325,000
+13.0%
108,354
+8.3%
0.00%
Q2 2022$2,943,000
-6.1%
100,025
+2.7%
0.00%
Q1 2022$3,133,000
-15.5%
97,372
+17.1%
0.00%
Q4 2021$3,707,000
-25.4%
83,145
-15.6%
0.00%
-100.0%
Q3 2021$4,970,000
-30.3%
98,510
+8.4%
0.00%0.0%
Q2 2021$7,129,000
+66.1%
90,880
+20.9%
0.00%0.0%
Q1 2021$4,292,000
-84.5%
75,181
-77.3%
0.00%
-75.0%
Q4 2020$27,732,000
+147.4%
331,093
+7.2%
0.00%
+100.0%
Q3 2020$11,211,000
+89.5%
308,854
+26.2%
0.00%
+100.0%
Q2 2020$5,916,000
+92.1%
244,686
+39.2%
0.00%0.0%
Q1 2020$3,079,000
+127.4%
175,843
+126.2%
0.00%
Q4 2019$1,354,000
+461.8%
77,742
+394.6%
0.00%
Q3 2019$241,000
-11.1%
15,719
+19.4%
0.00%
Q2 2019$271,000
+5.4%
13,170
+19.0%
0.00%
Q1 2019$257,000
+7.1%
11,069
-4.9%
0.00%
Q4 2018$240,000
+4.8%
11,640
+10.3%
0.00%
Q3 2018$229,000
+340.4%
10,554
+207.3%
0.00%
Q2 2018$52,000
-18.8%
3,434
+5.7%
0.00%
Q1 2018$64,0003,2500.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$339,037,00035.95%
Euclidean Capital LLC 323,749$27,117,0005.74%
Flagship Pioneering Inc. 2,730,263$228,687,0004.16%
Casdin Capital, LLC 1,310,000$109,726,0003.25%
A.R.T. Advisors, LLC 6,173$517,0002.39%
MARK ASSET MANAGEMENT LP 172,040$14,410,0001.73%
Temasek Holdings (Private) Ltd 4,410,457$369,420,0001.59%
Integral Health Asset Management, LLC 57,500$4,816,0001.43%
GILDER GAGNON HOWE & CO LLC 3,219,843$269,694,0001.34%
IRONWOOD INVESTMENT MANAGEMENT LLC 19,365$1,622,0000.95%
View complete list of DENALI THERAPEUTICS INC shareholders